Zelluna Immunotherapy
Blood & Organ Banks · Norway · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Ullernchausséen 64, Oslo, Oslo, 0379, No...Phone Number
+46 859478830Website
www.zelluna.comRevenue
$6.3 MillionIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
2
2
2
2
About Zelluna Immunotherapy
Zelluna is a pioneering company developing novel cell therapies specifically targeting solid cancers to improve treatment outcomes for cancer patients. The company focuses on its proprietary TCR-NK cell therapy platform, which aims to overcome existing challenges in solid cancer treatment. Zelluna's experienced team and strong intellectual property position enable it to pursue promising developments in the cell therapy field. Their mission is to transform cancer care by advancing innovative therapies that harness the immune system's capabilities.Explore more
Zelluna Immunotherapy Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Zelluna Immunotherapy your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if Zelluna Immunotherapy is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Zelluna Immunotherapy has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Zelluna Immunotherapy
Funding: Get notified immidiatlly once Zelluna Immunotherapy has new funding data
Zelluna Immunotherapy, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Zelluna Immunotherapy had a recent Job posting/layoffs
Product Launch: Get notified when Zelluna Immunotherapy launches new products
Earning: See what the market has to say on Zelluna Immunotherapy recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Zelluna Immunotherapy as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Zelluna Immunotherapy is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Zelluna Immunotherapy is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Zelluna Immunotherapy.
Zelluna Immunotherapy financials insights
Gather financial insights about Zelluna Immunotherapy, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$8.5M
Other Financing Round
$6M
Zelluna Immunotherapy Tech Stack
A closer look at the technologies used by Zelluna Immunotherapy
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Promotion
Executive Move
Executive Moves, Promotion
Promotion
Executive Move
Executive Moves, Promotion
Lateral Move
Executive Move
Executive Moves, Lateral Move
Promotion
Executive Move
Executive Moves, Promotion
Zelluna Immunotherapy News & Media
Zelluna receives Independent Data Monitoring Committee recommendation to continue patient enrolment in ZIMA-101
17 August 2026 – Zelluna ASA (OSE: ZLNA) today announced that the Independent Data Monitoring Committee (IDMC) has completed its review of the first patient’s safety data from the first-in-human ZIMA-101 study and has recommended that the study continues as planned.Zelluna ASA: Notice of EGM – experienced international biotech executive proposed for election to the Board and Board member steps down
Oslo, 17 August 2026: The Board of Directors of Zelluna ASA (the “Company”) hereby calls for an Extraordinary General Meeting to be held on 9 September 2026 at 13:00 CEST, regarding election of a new member of the Company’s Board of Directors (the “Board”).Zelluna ASA: Invitation to Second Quarter 2026 Results Webcast Presentation
Oslo, Norway, 13 August 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, invites to a webcast presentation of its second quarter 2026 results on Thursday, 20 August 2026.Zelluna ASA: New share capital registered
Oslo, 10 August 2026: Reference is made to the stock exchange announcement published by Zelluna ASA (the "Company") on 4 August 2026 regarding the Board of Directors resolution to issue 446,752 new shares to Inven2 AS pursuant to an authorisation granted by the Company's Annual General Meeting on 23 April 2026. The share contribution in the share capital increase was settled by way of set-off against the aggregate amount of EUR 791,666.70/NOK 8,834,604.54 owed by
Read more news
Top Blood & Organ Banks Companies
See more top companies
Frequently Asked Questions Regarding Zelluna Immunotherapy
Sign Up For FreeTo access detailed company insights
Zelluna is a pioneering company developing novel cell therapies specifically targeting solid cancers to improve treatment outcomes for cancer patients. The company focuses on its proprietary TCR-NK cell therapy platform, which aims to overcome existing challenges in solid cancer treatment. Zelluna's experienced team and strong intellectual property... Read More
